Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 5% IN PLASTIC CONTAINER vs MANNITOL 15%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.
Reduction of intracranial pressure and cerebral edema,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (e.g., oliguric phase),Facilitation of urinary excretion of toxic substances (e.g., salicylates, barbiturates)
Reduction of intracranial pressure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Promotion of diuresis in oliguric phases of acute renal failure (off-label),Cerebral edema (off-label)
50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.
1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.
Terminal elimination half-life: 1–2 hours (adults with normal renal function); prolonged to 24–48 hours in severe renal impairment.
Terminal elimination half-life approximately 0.25-1.5 hours in normal renal function; prolonged to 24-36 hours in renal impairment.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration, with minimal tubular reabsorption.
Mannitol is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration.
Renal: >90% as unchanged drug via glomerular filtration; negligible biliary or fecal elimination.
Primarily renal (90-100% as unchanged drug); negligible biliary/fecal elimination.
Negligible (<0.5%); no specific binding proteins.
Approximately 0-10% bound to plasma proteins (negligible binding).
0.5–0.6 L/kg; distributes primarily in extracellular fluid, does not cross cell membranes except under specific conditions (e.g., disrupted blood-brain barrier).
0.5-0.8 L/kg; primarily distributes in extracellular fluid (interstitial space).
IV: 100%. Oral: negligible (<10%) due to poor absorption; not administered orally for systemic effects.
Intravenous: 100% (only route used therapeutically); not administered orally due to minimal absorption (oral bioavailability < 5%).
Avoid use in anuria; GFR < 20 m L/min: contraindicated; GFR 20-50 m L/min: use with caution, monitor serum osmolality and fluid balance, reduce dose by 50% and extend interval to every 12-24 hours.
Contraindicated in anuria due to severe renal disease. For GFR <50 m L/min, use with caution and monitor serum osmolarity and renal function. No specific dose reduction defined; consider alternative therapy if GFR <20 m L/min.
No specific dose adjustment for hepatic impairment; caution in ascites due to potential volume overload.
No specific adjustment for Child-Pugh class. Use with caution in ascites or severe hepatic impairment due to risk of volume overload and electrolyte disturbances.
0.25-2 g/kg intravenously over 30-60 minutes, not to exceed 60 g in total dose; dose based on clinical indication and serum osmolality.
0.25-1 g/kg (1.67-6.67 m L/kg of 15% solution) intravenously over 30-60 minutes. Repeat doses as needed based on clinical response, up to 1-2 g/kg.
Start at lower end of dosing range (25-50 g), monitor renal function and serum osmolality; increased risk of volume overload and electrolyte disturbances; avoid if pre-existing renal impairment.
Initiate with lower doses (e.g., 0.5 g/kg) and titrate carefully due to increased risk of volume overload, electrolyte imbalance, and renal impairment. Monitor renal function, serum osmolarity, and fluid status closely.
None.
None
Monitor renal function, serum electrolytes, fluid balance, and osmolality during therapy.,Risk of volume overload, pulmonary edema, or heart failure in patients with impaired cardiac function.,May cause electrolyte disturbances (e.g., hyponatremia, hyperkalemia) and dehydration.,Use with caution in patients with severe renal impairment, anuria, or congestive heart failure.,Hypersensitivity reactions may occur.
May cause volume expansion, pulmonary congestion, or heart failure in patients with cardiac dysfunction. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with renal impairment, as accumulation can cause metabolic acidosis. Risk of osmotic nephrosis or acute kidney injury with high doses or prolonged use. May exacerbate intracranial hemorrhage due to increased cerebral blood volume.
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity to mannitol.
No specific food interactions. Maintain adequate fluid intake unless fluid restriction is prescribed (e.g., for hyponatremia or cerebral edema). Avoid excessive salt to prevent fluid retention.
No significant food interactions. Avoid excessive sodium intake to prevent fluid retention.
Mannitol is a pregnancy category C drug. In the first trimester, use is generally avoided due to lack of safety data; however, no teratogenic effects have been reported in animal studies at clinically relevant doses. In the second and third trimesters, administration may cause fetal dehydration, electrolyte imbalances, or osmotic shifts, particularly with high doses or prolonged infusion. Use only if clearly indicated (e.g., for cerebral edema in preeclampsia/eclampsia). Fetal monitoring for signs of fluid and electrolyte disturbance is recommended.
Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimesters: Use only if clearly needed, as osmotic diuresis may cause fetal dehydration, electrolyte imbalances, or altered placental blood flow. There is no evidence of direct teratogenicity.
It is unknown if mannitol is excreted in human breast milk. Due to its low oral bioavailability (approximately 20%), infant exposure via breastfeeding is expected to be minimal. However, caution is advised, especially in neonates with renal impairment. No M/P ratio is available. Consider the benefits of breastfeeding against the potential for infant effects.
Mannitol is not known to be excreted into human milk. M/P ratio is not established due to lack of data. Due to its high molecular weight and poor oral bioavailability, infant exposure via breastfeeding is likely negligible. Use with caution in lactating women only if clearly needed.
Pregnancy does not significantly alter mannitol pharmacokinetics. However, due to increased plasma volume and glomerular filtration rate during pregnancy, careful monitoring of therapeutic response and adverse effects is warranted. Dose adjustments are not routinely required but should be individualized based on maternal weight (obesity or edema), renal function, and clinical indication. Use the lowest effective dose with close monitoring of output and electrolytes.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume and renal clearance) may require higher doses to achieve desired effect. Monitor clinical response and adjust dosing based on urine output and serum osmolality.
Mannitol 5% is an osmotic diuretic. Monitor serum electrolytes, osmolality, and renal function before and during infusion. Avoid extravasation due to risk of tissue damage. Use in patients with intracranial hypertension requires careful titration to maintain cerebral perfusion pressure. Contraindicated in anuria, pulmonary edema, or active intracranial bleeding.
Monitor serum osmolality and electrolyte levels closely during therapy; use in cerebral edema requires maintaining serum osmolality 310-320 m Osm/L. Administer via in-line filter (0.22 micron) to prevent crystal emboli. Rapid infusion may cause transient hypervolemia; caution in heart failure or renal impairment. Onset of diuresis is 1-3 hours after IV administration.
This medication increases urine output; stay hydrated unless advised otherwise.,Report difficulty urinating, chest pain, or shortness of breath immediately.,Avoid sudden position changes to prevent dizziness from fluid shifts.,Inform your doctor if you have kidney disease, heart failure, or are pregnant.
This medication increases urine output to reduce fluid buildup.,Report any chest pain, difficulty breathing, or swelling in ankles/feet.,You may experience headache, nausea, or dry mouth.,Avoid excessive salt intake to prevent fluid retention.,Notify your doctor if you have kidney disease or heart conditions.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 5% IN PLASTIC CONTAINER vs MANNITOL 15%, answered by our medical review team.
MANNITOL 5% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.. MANNITOL 15% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 5% IN PLASTIC CONTAINER and MANNITOL 15% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 5% IN PLASTIC CONTAINER is: 50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.. The standard adult dose of MANNITOL 15% is: 1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining MANNITOL 5% IN PLASTIC CONTAINER and MANNITOL 15%. Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. MANNITOL 5% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol is a pregnancy category C drug. In the first trimester, use is generally avoided due to lack of safety data; however, no teratogenic effects have been reported in animal s. MANNITOL 15% is classified as Category A/B. Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.